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This knowledge-based activity is targeted for all phannacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

gresses (Figure 1). However, as a practicing pharmacist, it is
important to note that a majority of these cases are precipitated by a hypersensitivity reaction to certain medications.
Therefore, SJS and TEN are typically classified as severe cutaneous adverse drug reactions (SCARs).3 Common medications that elicit such a violent response from the body are
discussed below.

ACPE Universal Activity Number (UAN): 0048-0000-13-007-HO 1-P
Objectives
After completion of this program, the reader should be able
to:
1. Discuss the impact of Stevens-Johnson syndrome
(SJS) and toxic epidermal necrolysis (TEN).
2. Describe the three most commonly proposed
immunological mechanisms underlying SJS and TEN.
3. List medications commonly implicated in causing SJS
and TEN.
4. Discuss commonly used therapies for SJS and
TEN and the controversy surrounding them.
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are immunologic reactions that typically present
due to drug hypersensitivity. These reactions present with
serious mucocutaneous manifestations that can lead to significant morbidity and mortality. The pathogeneses of SJS
and TEN have yet to be clearly elucidated, but three potential
immunologic mechanisms have been defined in literature:
granulysin, Fas-FasL, and perforin and granzyme B. Medications have been immunologically linked as the primary
causative agents of SJS/TEN. Corticosteroids, intravenous
immunoglobulin administration (IVIG) and cyclosporine
have been employed as treatments; however, none have resulted in consistent positive outcomes. Pharmacists have a
significant role in identifying and discontinuing the offending
agent and recommending pharmacotherapy for treatment.
Overview
Drug hypersensitivity reactions are major clinical complications that can result in serious and life-threatening conditions. Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are severe immunologic reactions that clinically present with a widespread, cutaneous rash, target-like
lesions and skin detachment.l Stevens-Johnson syndrome
and toxic epidermal necrolysis are rare occurrences with
only one to two cases per one million individuals reported
annually.2The characteristic rash and lesions tend to localize
in the facial region, upper trunk and extremities of afflicted
individuals especially as the severity of the reaction pro-

2

Patients who develop SJS/TEN may present with a variety of
symptoms. Initial symptoms, which often precede cutaneous
involvement, can be non-specific and include fever, sore
throat and stinging eyes.z While the level of epidermal skin
detachment is utilized to determine the extent of the reaction, any of the mucous membranes in the body can be
impacted.3 All major organ systems containing mucosa!
membranes can be drastically impacted; gastrointestinal,
ocular, nasal, respiratory and genital membranes may potentially inflame and scar. 4 In severe cases, the scarring of organs results in a complete, irreversible loss of function that
can contribute to mortality. 4 It is also common for patients to
experience secondary infections of the skin or other organs
during the course of the syndrome.s Frequently, survivors of
SJS/TEN will experience ophthalmologic sequelae based on
the extent of ocular membrane damage incurred by the reaction.1 These potential complications illustrate that SJS/TEN
can result in both significant morbidity and mortality.
Stevens-Johnson syndrome and toxic epidermal necrolysis
have similar pathophysiology and clinical presentation but
are differentiated based on severity of disease.6 StevensJohnson syndrome is classified as presenting with skin detachment that affects 10 percent or less of the body.6 A patient will be diagnosed with TEN when 30 percent or more of
the skin becomes detached. This separation of the epidermis
from the underlying dermis is the direct result of immunemediated keratinocyte apoptosis, and the extent of apoptosis
determines the total percentage of skin impacted.s Overlap of
SJS and TEN can result when 10 to 30 percent of the body is
visibly impacted, making a distinct diagnosis difficult.6 Stevens-Johnson syndrome/toxic epidermal necrolysis
can be assessed with the SCORTEN (SCORe of Toxic Epidermal Necrolysis) system, a set of criteria utilized to predict
mortality outcomes for diagnosed individuals.7 Such criteria
include patient age, serum bicarbonate levels, heart rate and
the presentation of malignancies. 7

Immunologic Mechanism
Although the pathogeneses of SJS and TEN are not fully understood, the processes are known to be due to an immune
response. Re-challenging with the offending stimulus hastens
the onset and provokes a more severe reaction; therefore rechallenging is not recommended. The majority of cells that
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present in this immunological reaction are CD8+ Cytotoxic T·
lymphocytes (CTL), CD3+ T Cells, CDS6+ Natural Killer (NK)
cells and Natural Killer T -lymphocytes (NKT).3 The cytotoxic
response of CD8+ T cells in the skin is induced by the recog·
nition of the human leukocyte antigen (HLA) class I molecules that bind the drug or endogenous antigen promoting
clonal expansion of the cytotoxic lymphocytes. These cells
migrate to the skin and produce inflammatory mediators,
such as granulysin, perforin and granzyme B. These mediators then promote apoptosis of keratinocytes which causes
the separation of the epidermis from the dermis.6 There have
been recent findings that certain genotypes of the HLA-I
molecules may be associated with this reaction.s The complete mechanism of this reaction has not been clearly defined
in the literature, but there are currently three major theories
proposed to explain the mechanism.
Figure 1; Male presenting with SJS along chest, hands
and mucosal tissue around the mouth

The first proposed mechanism is granulysin as a mediator of
SJS and TEN. Granulysin is a cytolytic cationic protein stored
in the granules of CTLs and NK cells that is cytotoxic for tumor cells, bacteria, fungi and parasites. In SJS and TEN granulysin is released and binds to the keratinocyte surface via its
charge, promoting ion flux. Ion flux within the keratinocytes
causes increased permeability of the mitochondrial membrane resulting in mitochondrial damage and cytochrome-c
release, which in turn promotes apoptosis. Granulysin is a
chemo-attractant and pro-inflammatory activator of T cells
and monocytes, thus recruiting more cells to amplify this
reaction.3 In one study, granulysin was found to be a key
molecule responsible for keratinocyte death with a direct
correlation between amount of granulysin and severity of
tissue destruction. 3 Granulysin levels in serum were suggested to have clinical significance by acting as a potential
marker for predicting the prognosis, monitoring the progression and evaluating the therapeutic response for SJS/TEN.s
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array of other cells including keratinocytes. FasL, which is
prominently expressed by activated CTLs, binds and activates Fas to promote the trimerization of Fas receptors
which then activate Fas-associated death domain protein
(FADD). Fas-associated death domain protein causes the nucleation of inactive procaspase 8 allowing autoactivation of
procaspase 8 molecules to active caspase 8. Caspase 8, in
turn, activates the caspase cascade activating executioner
caspases which cause the degradation of cytoskeletal proteins and DNA.S The IVIG treatment strategy to prevent further apoptosis of keratinocytes is based upon the Fas-FasL
hypothesis.6
The perforin and granzyme B pathway is the last mechanism
proposed to produce the keratinocyte apoptosis. Activated
CTLs and NK cells produce perforin and secrete it into the
keratinocyte membrane. Perforin is a transmembrane protein that binds and forms a pore through the cell membrane.
Granzyme B is a protease released to enter the keratinocyte
activating the caspase cascade resulting in apoptosis. It has
been proposed that increasing levels of perforin, granzyme B,
TNF-alpha and FasL have been observed to be related to disease severity of drug hypersensitivity (from mild maculopapular rashes to severe TEN).5
Although the exact immune mechanism is unknown, medications have been immunologically linked as the primary
causative agents of this hypersensitivity reaction. Up to 77 to
95 percent of cases are directly associated with specific
medication use and more than 100 drugs have been associated with SJS/TEN. 1 Table 1 illustrates some of the most
common medications causing SJS and TEN. Other potential
causative agents are Mycoplasma pneumoniae, viruses and
one study implicated vaccines specifically for smallpox, anthrax and tetanus.B,9

http://missinglinkucsJedu//m/DermatologyG/ossary/stevensjohnson_zyndrome.html
This work is licensed under a Creative Commons Attribution-NonCommercialShareA/ike 2.5 License.

Activation of the apoptosis-inducing surface receptor Fas by
its corresponding ligand (FasL) has also been suggested as a
proposed mechanism of keratinocyte apoptosis. Fas is a
death domain receptor expressed on the surface ofa wide
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Table 1. Summary of Commonly Implicated Medications
of SJS and TEN.
Antibiotics

Cephalosporins, fluoroquinolones,
macrolides, sulfamethoxazole and
trimethoprim, penicillins

Anticonvulsants

Phenytoin, carbamazepine,*5
valproic acid, Phenobarbital

NSA!Ds

acetaminophen, ibuprofen, nimesulide,
diclofenac

Gout

Allopurinol*5

Other

Thiazides, multivitamins, ranitidine

*data currently recommendin9 Beno type testin9 before use of this
medication

Treatment Strategies
Finding an ideal therapeutic treatment option for SJS/TEN
patients has proven to be difficult. Due to the rarity of the
disease, obtaining and producing a case-controlled clinical
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trial with a large sample size of patients is a daunting task.
However, based on limited clinical data, the outcome of SJS/
TEN patients is largely dependent on three management
measures: supportive care, withdrawal of the suspecting
drug and active treatment.
First, SJS/TEN patients have an improved chance of survival
depending upon how quickly they are transferred to a burn
unit for supportive care. Aggressive skin care is available in
this setting, including critical fluid resuscitation, electrolyte
balance and enteral nutrition maintenance. Body temperature and other signs of infection and sepsis should be closely
monitored. Due to the potential eye complications, early ophthalmologic evaluation of these patients is criticaJ.7 Visual
acuity and scarring can be protected and prevented with application of short-term topical corticosteroids (fluorometholone ointment 0.1 percent, applied every one to two
hours), use of amniotic membranes and coverage of the ocular surface with symblepharon rings.1. 10 Moreover, patients
are often unable to eat or drink due to oral and esophageal
mucosa involvement from the disease. Viscous lidocaine or
other topical oral local anesthetics can be used before meals,
making food intake more tolerable,7.8 Finally, wound care
and skin treatment are necessary. Wounds should be treated
conservatively using nonadhesive dressings. 2 Avoid topical
sulfa containing medications and skin debridement, as blistered skin favors re-epithelialization.2
Second, upon diagnosis of SJS/TEN, the causative drug(s)
should be rapidly identified and withdrawn. 11 In concordance with identifying the risk drug within a patient's recent
history, analysis of drug intake and development of symptoms is necessary. The most likely offending drug that should
be suspected as a causative drug for SJS/TEN is one that has
been newly administered in the past four weeks. 11 Refer to
Table 1 for a summary of commonly implicated medications
of SJS and TEN.
Lastly, initiating an active treatment is a recommended
measure. However, there is no agreement as to which, if any,
treatment shortens the course of the disease.11 Current active modulating therapies for SJS/TEN include: corticosteroids, intravenous immunoglobulin administration (!VIG) and
cyclosporine.
Systemic corticosteroids are the most widely used for the
treatment of SJS/TEN. Yet, they are also the most controversial. High doses of systemic corticosteroids are administered

with the intent to suppress the intensity of immune reaction,
control the extension of the necrolytic process, decrease the
injury area, reduce fever and discomfort, and prevent damage to internal organs in the early stages of SJS/TEN.S Doses
of 1 mg to 2.5mg/kg/day for three days of oral methylprednisolone have been used.B.11 However, the use of corticosteroids with their robust immunosuppressive actions also poses
concern for increased risk of infection. Decreased host resistance, increased morbidity and complications (sepsis, leuk
ia, gastrointestinal ulcerations) and prolonged recovery for
skin healing are additional concerns; therefore, an antibacterial treatment is recommended. Bacterial and fungal cultures
should be taken two to three times a week from skin and mucosa! erosions.11 A prophylactic antibacterial treatment
(sodium penicillin, 10 million units twice daily) should be
administered immediately and adjusted according to the culture and sensitivity results.1 1 Stevens-Johnson syndrome/
toxic epidermal necrolysis patients should be closely monitored for the aforementioned potential complications, and
further controlled studies will be required to substantiate
whether systemic corticosteroids are ultimately beneficial.
The theory behind !VIG therapy is that !VIG may be able to
block immune mediators of SJS/TEN reactions.s Intravenous
immunoglobin administration is a promising strategy for
reducing disease progression, based on the Fas-FasL hypothesis: that blocking FasL binding to the Fas receptor will
interfere with the apoptotic signal, preventing cell death.6
Therapeutic doses have been set from 2 to 3.9g/kg, infused
over a two-, four-, or five-day period. 12 Further randomized
controlled studies are needed to support !VIG as a standard
therapy option.
Cyclosporine, a powerful anti-inflammatory and immunosuppressive agent, has not been closely studied but has been
shown to be beneficial in various case studies.7 Cyclosporine
affects cytotoxic T-lymphocyte mediated actions and inhibits
the inflammation caused by FasL, NK-kB, and TNF-a.s In addition to nephrotoxicity and hepatotoxicity, other potential
complications secondary to cyclosporine therapy, such as
hypomagnesemia and reversible posterior leukoencephalopathy, should also be carefully monitored.s
Recent advances in pharmacogenomic studies suggest a possible prevention strategy for the future cases of SJS/TEN.
Studies have found a strong genetic association between certain HLAs and specific drug-induced SJS/TEN.S Particular
HLA alleles were recognized as being main genetic determi-

Table 2. Associations Between Drug Hypersensitivity Reactions and ULA Alleles. 5
Causative Drug
Abacavir
Allopurinol
Carbamazepine
Carbamazepine
Carbamazepine
Methazolamide
Nevirapine
Oxicam NSA!Ds
Sulfonamide
4

ULA Allele(s)
B*57:01
B*58:01
B*15:02
B*15:11
A*31:01
HLA-B*59:01
DRBl*Ol:Ol
A2, B12
A29, Bl2, DR7
THE PHARMACY AND WELLNESS REVIEW

Hypersensitivity Reaction(s)
Abacavir hypersensitivity
SJS/TEN/DRESS
SJS/TEN
SJS/TEN
SJS/TEN/DRESS/MPE
SJS/TEN
MPE/DRESS
TEN
TEN
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nants of SJS/TEN in combination with specific causative
drugs. For example, HLA-8*15:02 is strongly associated with
carbamazepine (CBZ)-induced SJS/TEN.5 Table 2 outlines
further associations between drug hypersensitivity reactions
and HLA alleles. Chung et al. suggested that the strong genetic association between HLAs and specific drug-induced
SJS/TEN makes preventive screening tests prior to drug intake a possible practice to prevent SJS/TEN.5

Conclusion
Stevens-Johnson syndrome and toxic epidermal necrolysis
are significant cutaneous reactions often caused by medications due to an immune response. Although there is a low
incidence of SJS and TEN, these conditions have high rates of
morbidity and mortality. Pharmacists may have a significant
role in the prevention and treatment of SJS and TEN. Pharmacists can identify medications with potential to evoke this
immunological reaction as well as recommend HLA testing
for high risk drugs such as allopurinol and carbamazepine.
Additionally, pharmacists are foremost in ability to perform
medication review, an integral step in the treatment process.
Pharmacists may also recommend pharmacotherapy, as
there is a great deal of controversy surrounding treatment.
Further studies need to be performed to help distinguish
drug causes, the immunopathologic reaction and treatment
options to prevent and successfully improve patient outcomes.
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Assessment Questions

7.

Overview:
1.

SJS/TEN presents clinically with:
A. Myocardial infarction
B. Cutaneous rash
C. Excitability
D. Abnormal hair loss

2.

What percentage of epidermal detachment is
associated exclusively with SJS?
A. <10%
B. >30%
c. >55%
D. 10-30%

3.

Pharmacists can have a role in:
A. Identifying and discontinuing offending
agent
B. Recommending treatment options
C. Drug information regarding treatment
options
D. Recommending HLA testing for
carbamazepine and allopurinol
E. All of the above

Treatment:

The SCORTEN system:
A. Aids in determining what agent elicited the
immunologic response
B. Does not include age as a criterion
C. Assesses mortality outcomes
D. Is a computer system that tracks all patients
who currently have SJS/TEN

8.

The outcome of SJS/TEN patients is dependent on
which management measure?
A.
Supportive care
B. Withdrawal of the suspecting drug
C. Active treatment
D. All the above

9.

Prophylactic measures should be taken when
administering systemic corticosteroids as treatment
of SJS/TEN due to the possible risk of:
A. Seizures
B. Fatigue
C. Infection
D. Diarrhea

Immunology and Causative Drugs:
4.

True or False: Re-challenging with the offending
stimulus is not recommended due to a faster and
more severe response to the causative agent.
A. True
B. False

5.

Which immunological mediator is appropriately
matched to its mechanism of keratinocyte death?
A. Granulysin-Cation that creates ion flux
resulting in damage of the mitochondrial
membrane r esulting in apoptosis
B. Fas-FasL-death domain receptor trimerization which activates the caspase cascade
resulting in apoptosis
C. Perforin, granzyme 8- released by keratinocytes to stimulate their own apoptosis
D. All of the above
E. Two of the above

6.

6

Potential causative agents of SJS and TEN
A. Allopurinol
B. Acetaminophen
C. Cephalosporins
D. Phenytoin
E. All of the above

10. IVIG therapy can be used as a treatment option for
SJS/TEN because of its immunologic binding activity
of which mediator?
A. TNF-a
B. FasL
C. INF-y
D. Granzyme B
11. The HLA*B 15:02 allele was recognized as being
main genetic determinant of SJS/TEN in combination with which specific causative drug?
A. Carbamazepine
B. Methazolamide
C. Nevirapine
D. Allopurinol
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